Financing ·
Alkermes plc entered into Amendment No. 1 to its Credit Agreement on August 12, 2026, reducing the interest rate…
ALKSAlkermes plc.
Alkermes plc entered into Amendment No. 1 to its Credit Agreement on August 12, 2026, reducing the interest rate spread by 0.75% for the Term Loan A facility and 0.50% for the Term Loan B facility. The amendment affects outstanding principal amounts of $745,312,500.00 and $773,062,500 respectively, with maturities in February and August 2031. This financial restructuring lowers borrowing costs without altering the total debt volume or triggering new equity issuance. Alkermes plc operates in the pharmaceutical industry, developing and commercializing medicines for central nervous system disorders.